VOLUNTIS overview

Cambridge (USA), Paris (France) , October 18, 2021 - Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960 - " the Company "), a leader in the field of digital therapeutics, announces the successful completion of the Simplified Tender Offer (" the Offer ") initiated by AptarGroup, Inc. (" Aptar" - NYSE: ATR) to acquire the shares of Voluntis. As a result of the Offer, Aptar has exceeded the threshold of 90% of the share capital and theoretical voting rights of Voluntis and will...

Decline in commercial invoicing to € 1.5 million and IFRS revenue to € 1.3 million in H1 2021 Significant increase in deferred revenues to € 11.6 million at 30 June 2021 Significant reduction in operational expenses as part of the strategic roadmap announced in March 2020 Improvement in adjusted EBITDA, operating income and net income in H1 2021 Available cash at € 6.4 million and free cash flow at € -4.2 million at 30 June 2021 Around € 9 million in commercial invoicing expected in...

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, it has completed the acquisition of a majority stake in Voluntis (ENXTPA: ALVTX) from the company's reference shareholders and certain members of the management. The stake...

Cambridge (USA), Paris (France), September 2, 2021 11pm CET – Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gestion, Debiopharm Innovation Fund, SHAM Innovation Santé, Vesalius Biocapital and Indigo) announced today that following the signature of a share purchase agreement with AptarGroup, Inc. (NYSE: ATR) (“ Aptar ”) on July 22, 2021 and the approval of the...

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions announced today that following the entry into exclusive negotiations with Voluntis (ENXTPA: ALVTX) on June 21, 2021, and after completion of the consultation procedure of the employee representative bodies of Voluntis, it has signed on July 22, 2021 a share purchase agreement for the acquisition of a majority stake in Voluntis, representing approximately 64.6% of the...

Cambridge (USA), Paris (France), July 23, 2021, 11pm CET – Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gestion, Debiopharm Innovation Fund, SHAM Innovation Santé, Vesalius Biocapital and Indigo) announced today that following the entry into exclusive negotiations with AptarGroup, Inc. (NYSE: ATR) (“ Aptar ”) on June 21, 2021, and after completion of the...

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions announced today that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis (ENXTPA: ALVTX), a pioneer in digital therapeutics. This acquisition would complement Aptar’s existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health...

Cambridge (USA), Paris (France), June 22, 2021, 3:00 p.m. CET -- Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, and its main shareholders announced today that they have entered into exclusive negotiations with AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, with respect to a potential acquisition of all outstanding shares of Voluntis by Aptar. This...